Prospects for Johnson & Johnson's HIV vaccine effort have looked shaky since one of its shots failed to protect women in sub-Saharan Africa against infection with the virus in a phase 2
Johnson & Johnson has moved a step closer to the goal of developing a vaccine that can help prevent HIV infection, thanks to positive data from a phase 1/2a trial.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl